MedTrace Logo

Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

NCT03310632 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-07-02

Study results available
· View outcomes & findings →

Summary

Antroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg TID and 300 mg TID, clinical treatment duration of 4 weeks, to determine the MTD or MFD (based on PK and capsules strength) of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine. The extended Phase II will focus on the efficacy of antroquinonol with SOC. Safety and pharmacokinetic profiles will be studied in the proposed clinical trial.

Conditions

  • Pancreatic Neoplasm

Interventions

DRUG

Antroquinonol

SOC will via intravenous (IV) infusion on Days 1, 8, and 15. q8w for the first 48 weeks relative to first antroquinonol administration and q12w thereafter, until unacceptable toxicity or progressive disease.

DRUG

Antroquinonol

SOC will via intravenous (IV) infusion on Days 1, 8, and 15. q8w for the first 48 weeks relative to first antroquinonol administration and q12w thereafter, until unacceptable toxicity or progressive disease.

DRUG

Antroquinonol

SOC will via intravenous (IV) infusion on Days 1, 8, and 15. q8w for the first 48 weeks relative to first antroquinonol administration and q12w thereafter, up to and including 24 cycles or until unacceptable toxicity or progressive disease.

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • Golden Biotechnology Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2023-12-30
Completion
2024-01-02
FDA Drug
Yes

Countries

  • United States
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03310632 on ClinicalTrials.gov